Supplementary Figures S1-S2 from Lenalidomide and Eltrombopag for Treatment of Low- or Intermediate-Risk Myelodysplastic Syndrome: Result of a Phase II Clinical Trial
Year: 2025
Type: supplementary-materials
Abstract: Supplemental Figure 1. Overall Survival Responders vs Non-Responders Supplemental Figure 2. Overall Survival Among Groups
Authors: Jesus D. Gonzalez-Lugo, Suman Kambhampati, Abdulraheem Yacoub, William B. Donnellan, Jesus Berdeja, Prafulla Bhagat, Karen Fehn, Cassady Remy, Sakshi Jasra, Mohammed Kazemi, Kith Pradhan, Mimi Kim, Ioannis Mantzaris, R. Alejandro Sica, Nishi Shah, Mendel Goldfinger, Noah Kornblum, Kira Gritsman, Ira Braunschweig, Ulrich Steidl, Britta Will, Aditi Shastri, Amit Verma
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4416627556
Cites:
Cited by:
Related to: